Economics/Class Relations

As Coronavirus Cases Mount, So Do Concerns About Price-Gouging and Corporate Profiteering

It’s time to syndicalize the healthcare and pharmaceutical industries.

By Jessica Corbett

Common Dreams

As the number of global COVID-19 cases soared past 254,000 and the death toll topped 10,000 on Friday, concerns persisted—particularly in the United States—about healthcare costs related to the ongoing outbreak, limited testing and protective medical supplies, and how corporations may try to cash in on the public health crisis.

The Intercept‘s Naomi Klein, author of the 2007 book The Shock Doctrine: The Rise of Disaster Capitalism, warned earlier this week in a video about “coronavirus capitalism” that the U.S. and other governments are “exploiting” the COVID-19 pandemic “to push for no-strings-attached corporate bailouts and regulatory rollbacks.”

Klein took to Twitter Friday to highlight a New York Times report about how—although President Donald Trump on Wednesday signed legislation that orders free testing for COVID-19—even people with health insurance could face high medical bills, which experts worry will deterring people from seeking treatment.


Leave a Reply